A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

Table 2 Incidence of potentially-relevant 24-month follow-up readmissions

Readmissions, n (%)^a	Full cohort			Single-level cohort
	Group		P value	Group		P value
	V-CBA (n = 6,588)	rhBMP-2 (n = 9,584)	P value	V-CBA (n = 5,683)	rhBMP-2 (n = 8,505)	P value
Patients with all-cause 24-month follow-up readmissions^b	1,522 (23.1)	2,270 (23.7)	0.3954	1,076 (18.9)	1,531 (18.0)	0.1635
Re-admitted patients with potentially-relevant procedures/diagnoses^c
Subsequent lumbar fusion procedures	667 (10.12)	1150 (12.00)	0.0002*	485 (8.53)	768 (8.01)	0.3191
Cardiac complications	54 (0.82)	35 (0.37)	0.0002*	36 (0.63)	24 (0.25)	0.0022*
Deep vein thrombosis	6 (0.09)	4 (0.04)	0.3344	4 (0.07)	4 (0.04)	> 0.9999
Hematoma	23 (0.35)	31 (0.32)	0.7831	16 (0.28)	22 (0.23)	0.8687
Nervous system complications	19 (0.29)	15 (0.16)	0.0813	16 (0.28)	12 (0.13)	0.0813
Pneumonia	95 (1.44)	95 (0.99)	0.0114*	66 (1.16)	63 (0.66)	0.0113*
Pulmonary embolism	31 (0.47)	41 (0.43)	0.7191	25 (0.44)	32 (0.33)	0.5891
Sepsis	2 (0.03)	5 (0.05)	0.7081	1 (0.02)	3 (0.03)	0.6540
Surgical-site infection	20 (0.30)	23 (0.24)	0.4417	11 (0.19)	14 (0.15)	0.6879
Urinary tract infections	149 (2.26)	185 (1.93)	0.1594	91 (1.60)	127 (1.33)	0.6261

^aAll percentages were based on the total number of patients within each cohort who received V-CBA or rhBMP-2 during the initial procedure
^bPatients with more than one readmission were counted only once. Did not include patients who may have received follow-up treatment outside of the Premier Healthcare System
^cRepeats of the same procedure/diagnosis were counted only once. Did not include patients who may have received follow-up treatment outside of the Premier Healthcare System
^*Statistically significant, Fisher’s exact test

ISSN: 1749-799X